Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.55 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.48 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | F7 | P08709 | 1/20 | 0.47 |
| ▸ | F3 | P13726 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27530349 | 0.90 | ALDH1A1 (0.56) | TP53AKR1C3AKR1C2TSHRKMT2A | |
| SCHEMBL6852757 | 0.83 | TP53 (0.64) | TP53AKR1C3AKR1C2TDP1KEAP1 | |
| SCHEMBL31120368 | 0.82 | TP53 (0.62) | TP53AKR1C3AKR1C2TDP1KEAP1 | |
| SCHEMBL847769 | 0.81 | TSHR (0.61) | AKR1C3AKR1C2TSHRKMT2ATDP1 | |
| SCHEMBL7275462 | 0.81 | TP53 (0.80) | TP53TSHRTDP1KEAP1NFE2L2 | |
| SCHEMBL3765312 | 0.79 | TP53 (0.67) | TP53KMT2ATDP1GAAMEN1 | |
| SCHEMBL26464789 | 0.79 | GRIK1 (0.55) | TP53AKR1C3AKR1C2GRIK1GRIA1 | |
| SCHEMBL2744081 | 0.78 | GRIK1 (0.56) | TP53TSHRKMT2AGRIK1GRIA1 | |
| SCHEMBL6436941 | 0.78 | TP53 (0.54) | TP53AKR1C3AKR1C2KMT2ATDP1 | |
| SCHEMBL30532372 | 0.77 | AKR1C3 (0.57) | AKR1C3AKR1C2TSHRTDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841318-B2 | Substituted heterocycles as janus kinase inhibitors | INCYTE CORPORATION (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130274257-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2013-10-17 | — | — | US | disclosed |
| US-8513270-B2 | Substituted heterocycles as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2121692-B1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | INCYTE CORP (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-2121692-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | Incyte Corporation (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080188500-A1 | e.g. N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(trifluoromethyl)benzamide; Janus kinases inhibitor; anticarcinogenic agent; immune-related diseases, skin disorders, myeloid proliferative disorders | INCYTE CORPORATION | 2008-08-07 | — | — | US | disclosed |
| WO-2008079965-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188500-A1 | e.g. N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(trifluoromethyl)benzamide; Janus kinases inhibitor; anticarcinogenic agent; immune-related diseases, skin disorders, myeloid proliferative disorders | JAK3, JAK1, JAK2 | TP53 746/4885AKR1C3 2778/4885AKR1C2 2743/4885 |
| US-20130274257-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | TP53 800/4885AKR1C3 2018/4885AKR1C2 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.